<DOC>
	<DOCNO>NCT01674218</DOCNO>
	<brief_summary>This Phase I , single-center , double-blinded , randomize , placebo-controlled , five-period cross-over clinical study PA-824 evaluate effect PA-824 PA-824 plus moxifloxacin cardiac repolarization ( QT/QTc interval duration ) total 75 healthy male female participant , age 18 45 year . Moxifloxacin use active control . Participants blind treatment receive . The study consist screen period 26 day ; enrollment , 1 day ; five in-patient treatment period consist admission day ( except first treatment period , pre-dose day baseline ) , dose day two post-dosing day ; out-patient period least three day 10 day treatment period ; final visit 7 - 14 day discharge last treatment period .</brief_summary>
	<brief_title>Effect PA-824 PA-824 Plus Moxifloxacin QTc Interval Healthy Volunteers</brief_title>
	<detailed_description>This Phase I , single-center , double-blinded , randomize , placebo-controlled , five-period cross-over clinical study PA-824 evaluate effect PA-824 PA-824 plus moxifloxacin cardiac repolarization ( QT/QTc interval duration ) healthy male female participant . Moxifloxacin use active control . Participants blind treatment receive . The study consist screen period 26 day ; enrollment , 1 day ; five in-patient treatment period consist admission day ( except first treatment period , pre-dose day baseline ) , dose day two post-dosing day ; out-patient period least three day 10 day treatment period ; final visit 7 - 14 day discharge last treatment period . During study , subject receive one follow five treatment : Treatment A : PA-824 placebo moxifloxacin placebo ; Treatment B : PA-824 400 mg plus moxifloxacin placebo ; Treatment C : PA-824 1000 mg plus moxifloxacin placebo ; Treatment D : PA-824 placebo plus moxifloxacin 400 mg ; Treatment E : PA-824 400 mg plus moxifloxacin 400 mg . The primary objective evaluate effect single-dose administration PA-824 400 mg 1000 mg versus placebo QTcI interval . A total 75 randomize ( order least 60 evaluable ) healthy male female volunteer , age 18 45 year enrol .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Subject must 18 45 year age ( inclusive ) . Subject must healthy male female volunteer determine medical history , physical examination , 12lead ECG laboratory evaluation ( hematology , clinical chemistry urinalysis test ) within studydefined range Screening . ( See Appendix B acceptable range laboratory vital sign assessment ) . Body Mass Index ( BMI ) must 18 30 kg/m^2 inclusive . Subject must nontobacco/nicotine use ( 3month minimum ) . Subject must Tuberculin Skin Test/Purified Protein Derivative ( TST/PPD ) negative ( within previous 1 year ) Screening . The TST/PPD may omit subject present write evidence negative test previous 12 month . Subject must able give voluntary write informed consent study related procedure perform . If female , childbearing potential ( define ) agree avoid become pregnant day screen one week last dose use one follow acceptable method birth control addition use barrier method ( condom ) male partner ( even vasectomize ) : 1 . Hormonal contraceptive ; 2. intrauterine contraceptive device ; 3. diaphragm combination contraceptive jelly , cream , foam ; 4. spermicide ; 5. abstinence . Nonchildbearing potential define postmenopausal least 2 year , status bilateral tubal ligation least 1 year , status bilateral oophorectomy status hysterectomy . If male , agree avoid father child day screen three month last dose . All female subject must negative serum pregnancy test Screening , Enrollment ( Day2 ) checkin treatment period . Subject agree donate blood study 14 day end last treatment period . Subject agree comply study requirement . A history clinically significant acute illness ( resolve within 4 week screen ) history cardiac arrhythmia unexplained syncope presence cardiac , vascular gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic , psychiatric disease condition , opinion Site Principal Investigator ( PI ) , would jeopardize safety subject impact validity study result . Subject major surgery within 4 week screen . uncontrolled intercurrent illness ( i.e. , active infection ) fever ( oral temperature &gt; /=100 degrees Fahrenheit &gt; /= 37.7 degree Celsius ) screening . History lens opacity evidence lens opacity screen ophthalmologic examination clinically significant ophthalmic dysfunction disease . Subject abnormal diet 4 week precede screening . Abnormal diet define diet subject significant change eat habit ( e.g. , liquid diet ) unbalance diet ( e.g. , protein , high fat , low carbohydrate , etc. ) . Subject engage strenuous physical activity consume alcohol , grapefruit , caffeine methylxanthinecontaining beverages 48 hour report clinic enrollment discharge clinical site last treatment period . Previous participation study PA824 . History seizure ( febrile seizure childhood ) know suspected Central Nervous System ( CNS ) disorder may predispose seizure . History photosensitivity phototoxicity reaction use quinolones drug . History allergy severe sideeffects nitroimidazoles ( e.g. , Flagyl relate substance azole antifungal aromatase inhibitor ) . History allergy moxifloxacin fluoroquinolone antibiotic . History tendinopathy associate quinolones drug , include glucocorticoid , condition predisposes tendon rupture . Subject receive investigational drug clinical trial within 30 day prior screen . Subject use counter ( OTC ) medication , include vitamin herbal supplement , antacid , cough cold medication , within 7 day prior Day 1 treatment study drug study , unless opinion PI , substance would likely impact conduct study . Subject use prescription medication , except hormonal contraceptive , within 30 day prior Day 1 treatment study drug study , unless opinion PI , substance would likely impact conduct study . Subject current medical condition require treatment medication , either prescription OTC . Subject treat know CYP450 enzyme alter drug , azoles , antifungal , barbiturate , phenothiazine , cimetidine , carbamazepine , etc. , except hormonal contraceptive , within 30 day prior Day 1 treatment study drug . Subject treat drug know prolong electrocardiographic QT interval within 30 day prior Day 1 treatment study drug history excessive chronic caffeine ( &gt; 68 oz cup brew coffee daily ) , theophylline ( &gt; 600 mg/day ) , ephedrine ( &gt; 300 mg/day ) use.. Subject positive blood screen HIV , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody . Subject positive history alcohol abuse dependence and/or positive urine screen test alcohol drug abuse [ amphetamine , barbiturate , benzodiazepine , cocaine metabolite , marijuana , opiates , phencyclidine ( PCP ) ] screen checkin prior receive study drug . Subject baseline QTcF interval &gt; 440 msec ( male ) &gt; 450 msec ( female ) history prolong QTc interval family history Long QT Syndrome premature cardiac death sudden death without precede diagnosis condition could causative sudden death ( know coronary artery disease CHF terminal cancer ) . Subject clinically significant ECG abnormality opinion site principal investigator ( PI ) Screening , Enrollment ( Day2 ) , Baseline ( Day1 ) , checkin day prior receive study drug . Subject ECGs deem PI T wave morphology unfavorable consistently accurate QT measurement presence artifact readily eliminate . Subject hypokalemia , hypomagnesemia , hypocalcemia , history eat disorder . Subject serum creatinine , blood urea nitrogen ( BUN ) transaminase measurement upper limit normal range screening . Subject live person active Tuberculosis ( TB ) travel area endemic TB within past 12 month prior Screening . Women pregnant breastfeeding . Subject donate blood within past 30 day prior Day 1 treatment study drug . Subject employee family member employee Quintiles , DynPort Vaccine Company LLC ( DVC ) personnel participate conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>tuberculosis , safety , PA-824 , QTc interval , moxifloxacin , healthy volunteer , crossover</keyword>
</DOC>